{"filing":{"accession_number":"0001193125-26-342695","cik":"0001622229","ticker":"COGT","company_name":"Cogent Biosciences, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d132277d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526342695/d132277d8k.htm"},"events":[{"id":26735,"run_id":24309,"accession_number":"0001193125-26-342695","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company filed a prospectus supplement on August 10, 2026 to offer and sell up to $400,000,000 of shares of common stock under an at-the-market (ATM) offering agreement with Guggenheim Securities. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership dilution and capital structure, particularly given the substantial size ($400 million) of the offering.","company_name":"Cogent Biosciences, Inc.","ticker":"COGT","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27962,"accession_number":"0001193125-26-342695","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed a prospectus supplement on August 10, 2026 to offer and sell up to $400,000,000 of shares of common stock under an at-the-market (ATM) offering agreement with Guggenheim Securities. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership dilution and capital structure, particularly given the substantial size ($400 million) of the offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:09:27.865755+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27962,"accession_number":"0001193125-26-342695","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed a prospectus supplement on August 10, 2026 to offer and sell up to $400,000,000 of shares of common stock under an at-the-market (ATM) offering agreement with Guggenheim Securities. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership dilution and capital structure, particularly given the substantial size ($400 million) of the offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:09:27.865755+00:00","company_name":"Cogent Biosciences, Inc.","ticker":"COGT","filing_date":"2026-08-10"}]}